November 8, 2023 News by Marisa Wexler, MS High blood NfL levels predict greater MS disability in year or two: Study Elevated blood levels of neurofilament light chain (NfL), an established biomarker of nerve damage, are associated with a higher risk of near-term disability worsening in people with multiple sclerosis (MS), according to a large study. Findings imply that there’s usually a window of time — about a year or…
August 15, 2023 News by Marisa Wexler, MS Diet shows no association with relapses, disability progression A higher quality diet is associated with reductions in certain types of brain lesions in multiple sclerosis (MS), but no link was seen between a good diet and the risk of MS relapses or disability progression, a new study from Australia indicates. The study, “Higher…
March 14, 2023 News by Margarida Maia, PhD Higher blood levels of Ocrevus lower confirmed disability progression risk Higher blood levels of Ocrevus (ocrelizumab) is associated with a significantly lower risk of confirmed disability progression during treatment in people with relapsing and progressive forms of multiple sclerosis (MS), according to an analysis of data from three Phase 3 clinical trials. Notably, the lower disability progression rates reported in…
April 3, 2020 News by Joana Carvalho, PhD Ocrevus Lowers Progression Risk in More Disabled MS Patients, Study Suggests For multiple sclerosis (MS) patients with considerable disability, Ocrevus (ocrelizumab) appears to lower the risk of continued progression in both relapsing and primary progressive forms of the disease, data from an exploratory and post-hoc analysis of three Phase 3 trials report. These findings were in the study, “…
June 6, 2016 News by Patricia Silva, PhD #CMSC16 – Ocrevus (Ocrelizumab) in PPMS Prevented Disability Progression, Lowered MRI Lesion Volume, Study Shows Data recently presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting showed that Roche/Genentech’s investigational drug ocrelizumab (Ocrevus) lowered the risk of disability progression in primary progressive multiple sclerosis (PPMS), a condition for which no approved treatments exist. The study was presented during the “…
June 6, 2016 News by Patricia Inacio, PhD #CMSC16 – Delayed-release Dimethyl Fumarate Benefits Newly Diagnosed MS Patients, According to Study Newly diagnosed patients with relapsing-remitting multiple sclerosis (RRMS) show significant improvements when treated with delayed-release dimethyl fumarate (DMF), especially in terms of reduction in confirmed disability progression. The study, “Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Multiple Sclerosis Using a Composite Measure of Disability,” was recently presented at the…
